Dexamethasone‐cyclophosphamide Pulse Therapy for Pemphigus

Pasricha, JS; Khaitan, Binod K.; Raman, Rajeev; Chandra, Mithilesh

doi:10.1111/j.1365-4362.1995.tb04430.x

Cited by 115 publications

(113 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Common side effects of pyogenic skin infections and candidiasis were similar to that noted in previous studies. Generalised pigmentation of skin was reported in one patient which was also observed by Pasricha et al and Dhabhai et al 3,8 Acneiform eruptions were seen in one patient in our study which was not reported in the previous studies. Pasrisha et al have reported generalised pruritus which was not seen in our study.…”

Section: Discussionsupporting

confidence: 49%

See 1 more Smart Citation

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

2016

View full text Add to dashboard Cite

Background: Systemic lupus erythematosus (SLE) is always a challenge to the treating dermatologists. Pulse therapy is the use of supra pharmacological doses of drugs to achieve a desired therapeutic effect. The success of dexamethasone cyclophosphamide pulse therapy (DCP) in autoimmune bullous diseases has prompted dermatologists to use DCP in SLE but very few studies are available which objectively measure the outcome of DCP therapy in SLE. The aim of our study is to study the efficacy of dexamethasone cyclophosphamide pulse in patients with SLE and to use objective scoring systems to assess efficacy.Methods: 20 SLE patients who satisfied the inclusion criteria were administered intravenous dexamethasone 100 mg over three days with cyclophosphamide 500 mg on day1, followed by oral cyclophosphamide 50 mg daily. In patients whom cyclophosphamide cannot be used oral azathioprine was given. Response to treatment was assessed using CLASI (cutaneous lupus area severity index), clinical evaluation of dermatological and systemic symptoms and laboratory parameters such as ANA, Anti dsDNA, ESR etc.Results: All the patients showed clinical improvement with statistically significant fall in CLASI scores and anti dsDNA values. The mean duration of pulses required to achieve remission was 9 pulses. No major adverse effects were observed in any of the patients.Conclusions: Dexamethasone cyclophosphamide pulse therapy is an effective and safe option in the management of patients with SLE.

show abstract

Section: Discussionsupporting

confidence: 49%

“…Pasrisha et al have reported generalised pruritus which was not seen in our study. 3 Menstrual irregularities were seen in 35% of our patients. Previous studies have not mentioned any reports of menstrual irregularities.…”

Section: Discussionmentioning

confidence: 98%

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

2016

View full text Add to dashboard Cite

show abstract

“…In Rituximab group follow up period is 2 years unlike the DCP group where it is about ten years [6][7][8][9][10][11].…”

Section: Discussionmentioning

confidence: 99%

To Compare the Cost of Rituximab and DCP Therapy in Pemphigus in a Government Tertiary Hospital

Kanchan¹,

Kamoji²,

Patil³

2017

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

show abstract

“…dexamethasone has been successfully used as a substitute. [8][9][10] The purpose of this study is to report our experience on the outcome of therapy with a single i.v. pulse of dexamethasone as compared to i.v.…”

Section: Introductionmentioning

confidence: 99%

Intravenous dexamethasone vs methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection

Tandon

Verma

Chawla

et al. 2008

Eye

View full text Add to dashboard Cite

Dexamethasone‐cyclophosphamide Pulse Therapy for Pemphigus

Abstract: If substantiated by further follow-up, this treatment schedule may prove curative in this potentially fatal disease.

Cited by 115 publications

References 33 publications

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

To Compare the Cost of Rituximab and DCP Therapy in Pemphigus in a Government Tertiary Hospital

Intravenous dexamethasone vs methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection

Contact Info

Product

Resources

About